BRIEF published on 11/25/2025 at 18:38, 23 days 5 hours ago ABIONYX Pharma publie ses prévisions d'activité pour le troisième trimestre 2025 Mise À Jour Financière Revenu ABIONYX Pharma 3e Trimestre 2025 Recherche Sur La Septicémie
PRESS RELEASE published on 11/25/2025 at 18:33, 23 days 6 hours ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 23 days 6 hours ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
BRIEF published on 11/12/2025 at 07:05, 1 month 6 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 11/12/2025 at 07:05, 1 month 6 days ago ABIONYX Pharma en discussions avancées avec l'IHU SEPSIS Partenariat Stratégique ABIONYX Pharma Sepsis IHU SEPSIS Biomédicaments
PRESS RELEASE published on 11/12/2025 at 07:00, 1 month 6 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions stratégiques avancées avec l’IHU SEPSIS, 1er centre mondial dédié au sepsis, pour une alliance structurante et transformante dans le traitement global du sepsis Alliance ABIONYX Pharma Sepsis Discussions Stratégiques IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 1 month 28 days ago Validation génétique de l'ApoA-I dans le sepsis par ABIONYX Pharma ABIONYX Pharma Thérapies Innovantes Apolipoprotéine A-I Septicémie Validation Génétique
BRIEF published on 10/21/2025 at 18:54, 1 month 28 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 1 month 28 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
PRESS RELEASE published on 10/21/2025 at 18:49, 1 month 28 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce une validation historique dans la revue NATURE confirmant la causalité génétique de l'apolipoprotéine A-I (ApoA-I) dans le sepsis. Une avancée majeure dans le traitement de la septicémie Validation Historique ABIONYX Pharma Nature Septicémie Causalité Génétique
Published on 12/19/2025 at 00:00, 35 minutes ago LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor
Published on 12/18/2025 at 23:10, 1 hour 25 minutes ago Air T, Inc. Announces Closing of Regional Express Acquisition
Published on 12/18/2025 at 23:05, 1 hour 30 minutes ago BlackBerry Reports Third Quarter Fiscal Year 2026 Results
Published on 12/18/2025 at 22:45, 1 hour 50 minutes ago Stabilis Solutions Announces Multi-Year Marine Bunkering Agreement with Carnival Coprporation at Proposed Galveston LNG Liquefaction Facility
Published on 12/18/2025 at 22:05, 2 hours 30 minutes ago Abivax fait son entrée au sein de l'indice Nasdaq Biotechnology
Published on 12/18/2025 at 22:05, 2 hours 30 minutes ago Abivax to be Added to Nasdaq Biotechnology Index
Published on 12/18/2025 at 20:09, 4 hours 26 minutes ago EQS-Adhoc: The Grounds Real Estate Development AG: Conversion of the EUR 17 million bond issued in 2023/2024 into a hybrid bond
Published on 12/18/2025 at 19:30, 5 hours 5 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE EN REPONSE ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES DANS LE CADRE DE L’OFFRE PUBLIQUE DE RETRAIT
Published on 12/18/2025 at 19:30, 5 hours 5 minutes ago Prodware: COMMUNIQUE DU 18 DECEMBRE 2025 RELATIF A LA MISE A DISPOSITION DE LA NOTE D’INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES , NOTAMMENT JURIDIQUES, FINANCIERE DE PHAST INVEST
Published on 12/18/2025 at 18:30, 6 hours 5 minutes ago Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 18:30, 6 hours 5 minutes ago Schneider Electric finalise l’opération d’acquisition des 35% restants du capital de sa JV existante en Inde
Published on 12/18/2025 at 17:45, 6 hours 50 minutes ago Cie du Bois Sauvage: Vernietiging eigen aandelen
Published on 12/18/2025 at 17:45, 6 hours 50 minutes ago Damartex réaffirme son éligibilité au PEA-PME
Published on 12/18/2025 at 17:45, 6 hours 50 minutes ago Cie du Bois Sauvage : Cancellation of own shares
